NCT04310527View on ClinicalTrials.gov

Bioavailability of Enasidenib (CC-90007) Sprinkle Formulation Relative to the Reference Tablet Formulation and Effect of Food on the Pharmacokinetics of Sprinkle Formulation in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 9, 2019

Primary Completion Date

November 27, 2019

Study Completion Date

December 9, 2019

Conditions
Healthy Volunteers
Interventions
DRUG

Enasidenib

Enasidenib

Trial Locations (1)

78744

PPD Development, LP, Austin

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY

NCT04310527 - Bioavailability of Enasidenib (CC-90007) Sprinkle Formulation Relative to the Reference Tablet Formulation and Effect of Food on the Pharmacokinetics of Sprinkle Formulation in Healthy Adults | Biotech Hunter | Biotech Hunter